<DOC>
	<DOC>NCT00424775</DOC>
	<brief_summary>The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.</brief_summary>
	<brief_title>A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Chemotherapynaive patients who are histologically or cytologically diagnosed NSCLC with stage IIIB (not applicable of radical thoracic radiation) or stage IV Patients with normal organ function and bone marrow function Given radical thoracic radiation for NSCLC or radiation for other than original lesion within 3 weeks Any peripheral neuropathy above grade 2 Any ascites, pleural effusion or pericardiac effusion which requires treatment Any uncontrolled concomitant illness Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Non-Small Cell Lung Cancer (NSCLC)</keyword>
</DOC>